Corcept Therapeutics Incorporated

NasdaqCM:CORT 주식 리포트

시가총액: US$6.3b

Corcept Therapeutics 향후 성장

Future 기준 점검 6/6

Corcept Therapeutics (는) 각각 연간 48.7% 및 21.7% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 49.6% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 31.5% 로 예상됩니다.

핵심 정보

48.7%

이익 성장률

49.62%

EPS 성장률

Pharmaceuticals 이익 성장14.4%
매출 성장률21.7%
향후 자기자본이익률31.46%
애널리스트 커버리지

Low

마지막 업데이트13 May 2026

최근 향후 성장 업데이트

Recent updates

내러티브 업데이트 • May 11

CORT: New Ovarian Cancer Therapy Approval Will Support Future Upside

Analysts have raised Corcept Therapeutics' implied fair value target to $73.40 from $67.40. This reflects updated assumptions that indicate higher revenue growth and profit margins, slightly offset by a higher discount rate and a lower future P/E multiple following recent mixed price target revisions and a rating upgrade on the stock.
Seeking Alpha • May 04

Corcept: 'Strong Buy' On Lifyorli FDA Approval And ALS Phase 3 Advancement

Summary Corcept Therapeutics Incorporated remains a Strong Buy following early FDA approval of Lyforli [relacorilant] plus nab-paclitaxel for platinum-resistant ovarian cancer [PROC]. The company expects further upside from European approval, additional oncology indications, and a triple-combo study with Avastin, with key data and decisions anticipated by year-end. Phase 2 data for dazucorilant in ALS showed significant 1- and 2-year survival benefits, supporting a planned phase 3 study targeting overall survival as a primary endpoint. CORT 2026 revenue guidance was raised to $950–$1,050 million, driven by strong Lyforli uptake and robust Korlym sales, though risks include EU approval uncertainty and potential pricing pressures. Read the full article on Seeking Alpha
내러티브 업데이트 • Apr 25

CORT: Ovarian Cancer Approval Will Support Future Upside Despite Patent Setback

Analysts have adjusted their price targets on Corcept Therapeutics, with changes such as H.C. Wainwright moving its target to $67, alongside offsetting increases from firms like Canaccord. These moves reflect updated views on patent risk, generic competition and the long term earnings profile implied by largely unchanged fair value, revenue growth, profit margin and future P/E assumptions.
내러티브 업데이트 • Apr 11

CORT: Ovarian Cancer Approval Will Support Future Upside Despite Generic Headwinds

Corcept Therapeutics' updated analyst price target has been reset to $67, with analysts citing a tempered revenue growth outlook, slightly stronger expected profit margins, and an unchanged fair value and future P/E assumption. Analyst Commentary Recent Street research on Corcept Therapeutics reflects a mixed but engaged view, with several firms recalibrating price targets and ratings after legal and regulatory updates.
내러티브 업데이트 • Mar 27

CORT: Ovarian Cancer Approval Will Drive Future Upside Despite Generic Risk

Corcept Therapeutics' updated analyst price target has moved to $67.40 from $65.40. Analysts cite refined fair value assumptions and a slightly higher future P/E multiple as they reassess the stock following mixed target changes across recent research coverage.
내러티브 업데이트 • Mar 10

CORT: Future Generic Ruling And Oncology Data Will Drive Upside

Analysts have reduced their price target on Corcept Therapeutics to $67 from $105, reflecting lower fair value assumptions and revised expectations for revenue growth and profit margins after the court ruling that allows Teva's generic Korlym to participate in the Cushing's syndrome market. Analyst Commentary Recent research on Corcept Therapeutics clusters around the patent ruling on Teva's generic Korlym and its implications for the Cushing's syndrome market.
내러티브 업데이트 • Feb 24

CORT: Future Court Ruling And Oncology Data Will Drive Long Term Upside

Analysts have reduced their fair value estimate for Corcept Therapeutics from $94.20 to $76.40 and the implied future P/E from 18.66x to 16.90x, reflecting a lower price target from $105 to $67 following the court decision allowing Teva's generic Korlym to compete, along with a more cautious view on revenue growth and profit margins. Analyst Commentary Recent research updates on Corcept Therapeutics focus heavily on the legal outcome around Teva's generic Korlym and what that could mean for valuation, growth expectations, and execution risk.
내러티브 업데이트 • Feb 09

CORT: Future Regulatory And Oncology Outcomes Will Drive Long Term Upside

Analysts have raised their price target on Corcept Therapeutics by about $1, citing updated models that reflect steady assumptions for fair value, revenue growth, profit margins and future P/E. Recent research maintains the overall investment thesis despite regulatory developments.
내러티브 업데이트 • Jan 26

CORT: Future Endocrine And Oncology Decisions Will Drive Long Term Upside

Narrative Update: Corcept Therapeutics Analysts have lifted their fair value estimate for Corcept Therapeutics to $94.20 from $91.00, citing updated assumptions around higher revenue growth, stronger profit margins, and a slightly lower future P/E multiple in their latest models. Analyst Commentary Recent research on Corcept Therapeutics has focused on how its Cushing's syndrome franchise could support long term growth, while also highlighting uncertainties around future positioning and execution.
내러티브 업데이트 • Jan 10

CORT: Upcoming Endocrine And Oncology Decisions Will Shape Long Term Upside

Analysts have reset their price target framework for Corcept Therapeutics from about $127 to roughly $91, reflecting updated assumptions around revenue growth, profit margins, and a higher future P/E multiple, informed in part by recent coverage that compares relacorilant and Korlym with existing Cushing's syndrome treatments. Analyst Commentary Street research around Corcept Therapeutics is limited in the recent set of notes, but one new initiation helps frame how some investors might think about both the clinical and valuation setup for the stock.
분석 기사 • Jan 01

The Price Is Right For Corcept Therapeutics Incorporated (NASDAQ:CORT) Even After Diving 56%

Corcept Therapeutics Incorporated ( NASDAQ:CORT ) shareholders that were waiting for something to happen have been...
내러티브 업데이트 • Dec 17

CORT: Upcoming Ovarian Cancer Decisions May Drive Upside Despite Pharmacy Transition Risks

Analysts have modestly trimmed their price target on Corcept Therapeutics to $127.20 from $134.50, reflecting a slightly higher discount rate. They also point to stronger long term revenue growth, expanding profit margins and a lower future P E multiple supported by continued confidence in the commercial potential of Korlym and relacorilant.
분석 기사 • Oct 07

Corcept Therapeutics Incorporated (NASDAQ:CORT) Stocks Shoot Up 30% But Its P/E Still Looks Reasonable

The Corcept Therapeutics Incorporated ( NASDAQ:CORT ) share price has done very well over the last month, posting an...

이익 및 매출 성장 예측

NasdaqCM:CORT - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수
12/31/20281,5505342254905
12/31/20271,2902531323025
12/31/2026989841081505
3/31/202676947120120N/A
12/31/202576198142142N/A
9/30/2025741105163163N/A
6/30/2025716132180182N/A
3/31/2025685133177179N/A
12/31/2024675140196198N/A
9/30/2024629140142144N/A
6/30/2024570125123124N/A
3/31/2024524117125125N/A
12/31/2023482105127127N/A
9/30/202345091154155N/A
6/30/202342894135135N/A
3/31/202341494111111N/A
12/31/2022402101120120N/A
9/30/2022398117136136N/A
6/30/2022392113151151N/A
3/31/2022380112177178N/A
12/31/2021366113167168N/A
9/30/2021353106153154N/A
6/30/202134398134135N/A
3/31/202134099143144N/A
12/31/2020354106151152N/A
9/30/2020356109164165N/A
6/30/2020351114173173N/A
3/31/2020335106145146N/A
12/31/201930694N/A136N/A
9/30/201928587N/A109N/A
6/30/201926878N/A115N/A
3/31/201925876N/A105N/A
12/31/201825175N/A116N/A
9/30/2018238152N/A119N/A
6/30/2018216148N/A85N/A
3/31/2018189142N/A86N/A
12/31/2017159129N/A61N/A
9/30/201713035N/A41N/A
6/30/201710924N/A39N/A
3/31/20179313N/A25N/A
12/31/2016818N/A18N/A
9/30/2016725N/A18N/A
6/30/2016641N/A10N/A
3/31/201656-2N/A8N/A
12/31/201550-6N/A3N/A
9/30/201544-11N/A-2N/A
6/30/201538-17N/A-9N/A

애널리스트 향후 성장 전망

수입 대 저축률: CORT 의 연간 예상 수익 증가율(48.7%)이 saving rate(3.5%)보다 높습니다.

수익 vs 시장: CORT 의 연간 수익(48.7%)이 US 시장(16.8%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 수익: CORT 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.

수익 대 시장: CORT 의 수익(연간 21.7%)이 US 시장(연간 11.6%)보다 빠르게 성장할 것으로 예상됩니다.

고성장 매출: CORT 의 수익(연간 21.7%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: CORT의 자본 수익률은 3년 후 31.5%로 높을 것으로 예상됩니다.

성장 기업 찾아보기

7D

1Y

7D

1Y

7D

1Y

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/05/20 06:21
종가2026/05/20 00:00
수익2026/03/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Corcept Therapeutics Incorporated는 18명의 분석가가 다루고 있습니다. 이 중 5명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Tazeen AhmadBofA Global Research
Debjit ChattopadhyayBrean Capital Historical (Janney Montgomery)
David BuckB. Riley Securities, Inc.